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Background 
PET-CT scan is recommended to triage patients for exenterative surgery and surveillance 
after treatment for advanced cervical cancer.  
Objective 
To evaluate diagnostic accuracy of additional whole body PET-CT compared to CT/MRI in 
women with suspected recurrent/persistent cervical cancer and in asymptomatic women as 
surveillance 
Design 
Systematic reviews.  Subjective elicitation to supplement diagnostic information  
 
Search strategy/Selection criteria/Data collection and Analysis  
Searching of electronic databases to May 2010. Studies in women with suspected recurrent/ 
persistent cervical cancer and in asymptomatic women undergoing follow-up with sufficient 
numeric data included. We calculated sensitivity, specificity, and corresponding 95% 
confidence intervals. Meta-analyses employing  bivariate model that included random-effects 
term for between-study variation.   
 
Subjective elicitation 
Prevalence of recurrence and the accuracy of imaging elicited using the allocation of point’s 
technique. Coherence of elicited subjective probabilities with estimates in the literature 
examined.  
Results 
We identified 12 relevant studies. None directly compared additional PET-CT to MRI or CT 
separately. CT and MRI studies used older protocols and majority did not distinguish 
between asymptomatic and symptomatic women. Meta-analysis of PET-CT studies showed 
sensitivity of 92.2% (95% CI 85.1-96.0) and specificity of 88.1% (95% CI 77.9-93.9). 
Sensitivity and specificity for MRI was 82-100% and 78-100% and CT between 78-93% and 
0-95%. Subjective elicitation provided estimates comparable to literature. Subjective 
estimates of increase in accuracy from additional PET-CT were less than elicited increase 
required to justify use in surveillance.  
Conclusion 
Evidence to support additional PET-CT is scarce, of poor quality and does not distinguish 
between application for surveillance and diagnosis.  Guidelines recommending PET/CT in 
cervical cancer need to be reconsidered. 
Key words PET-CT, CT, MRI, recurrent cervical cancer, exenteration, accuracy 
3 
 
Introduction 
 
Cervical cancer was diagnosed in 2,851 women in the UK in 2010 and 936 deaths from 
cervical cancer in the UK were noted. 1Early stage cervical cancer is treated by surgery or 
chemoradiation (stages 1-IIA) whilst advanced stage cervical cancer (IIB-IIIB) is treated 
predominantly by chemoradiation. Chemotherapy alone is reserved for metastatic cancer at 
presentation. Recurrence is more common in advanced cervical cancer (30%) than in early 
stage cervical cancer (6%). 2 3 Currently surveillance is based on clinical examination at 
regular follow-up visits to detect recurrence. If recurrence is suspected, either on the basis of 
symptoms or examination, computed tomography (CT) or magnetic resonance imaging is 
used to confirm and define the extent of recurrence. 4  Neither modality can distinguish 
between radiation induced fibrosis and malignancy.   
Survival in women presenting with symptoms of recurrence – e.g. pain/bleeding/fistulae from 
locally advanced cancer or cachexia from distant metastases is substantially worse than in 
asymptomatic women detected at surveillance. 5-7 Treatment options for recurrent cervical 
cancer encompass radical surgery (salvage hysterectomy or pelvic exenteration), 
chemoradiotherapy and palliative treatment (which can be chemotherapy or radiotherapy).   
In carefully selected patients, with pelvis confined or central recurrence, exenterative surgery 
involving the removal of bladder, uterus and vagina, and/or rectosigmoid is potentially 
curative. It is therefore reasonable to assume that improving early detection of recurrence in 
asymptomatic women will improve survival by identifying women with pelvis confined 
recurrence where salvage surgery can be undertaken. However, salvage surgery carries risk 
for significant morbidity and mortality, particularly where the pelvis has been irradiated. The 
long term impact on the patient, including psychosocial is also considerable. Accurately 
triaging patients with distant metastases to receive palliative therapy and patients with 
potentially curative central pelvic recurrence to exenterative surgery is critical to the 
management of women with recurrent cervical cancer.     
Positron emission tomography (PET) uses 18-F fluorodeoxyglucose (FDG) uptake in 
metabolically active tissues for detection. PET-CT combines PET with CT to define 
anatomical images.  The CT images are used for localization and characterization of 
abnormal activity on the PET scans, and therefore to improve the specificity of the PET scan 
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interpretation. However, registration CT scans performed as part of an integrated PET-CT 
study are almost universally done to a relatively low-dose protocol using lower exposure 
factors and thicker slices than dedicated diagnostic CT. Intravenous and oral contrast are not 
generally used. As a consequence resolution and sensitivity for lesions for the registration CT 
alone will be lower than for a dedicated diagnostic CT. 
 Whole body PET-CT has shown promise in surveillance, improved detection of recurrence 
and distant metastasis and can predict survival outcome if performed three months after 
treatment.8 9 However, PET-CT is also expensive, the equipment alone costing about 2 
million pounds Sterling. False positives can occur in other metabolically active conditions 
e.g. inflammation or sepsis.  
PET-CT has been recently introduced into clinical practice to triage patients for exenterative 
surgery and is endorsed for this use by national guidelines.10 11 PET-CT is also recommended 
as surveillance after treatment for advanced stage cervical cancer. 10 However, the 
effectiveness of PET-CT in accurately triaging patients to potentially curative or palliative 
treatment and the diagnostic accuracy of PET-CT in asymptomatic women as surveillance for 
recurrence are not known. We performed systematic reviews of test accuracy and subjective 
elicitation to determine diagnostic accuracy of whole body PET-CT in addition to CT/ MRI 
in  women following treatment  for  cervical cancer. .  
In identifying the additional value of PET/CT over standard CT/MRI imaging, we sought 
evidence to answer 3 specific questions – 1. Value of routine PET-CT in follow-up of  
asymptomatic women after treatment for cervical cancer  
2  Value of PET-CT imaging in detecting a recurrence in symptomatic women 
3. Value of PET-CT imaging in recurrence to define a treatment strategy 
 
Methods 
Systematic reviews of test accuracy 
A generic protocol was developed for undertaking the systematic reviews of test accuracy, diagnostic 
and therapeutic yield. Systematic reviews of test accuracy were conducted using established 
methods in line with the recommendations of the Cochrane Diagnostic Test Accuracy 
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Working Group (http://srdta.cochrane.org/handbook-dta-reviews). Comprehensive searches from 
inception to May 2010 were conducted in MEDLINE, Embase, Science Citation Index, The 
Cochrane Library, MEDION, Cochrane Database of Systematic Reviews, Database of 
Abstracts of Reviews of Effects, the Health Technology Assessment Database, Clinical 
Trials.com as well as a search of internet resources (UK Clinical Research Network Portfolio, 
specialist search gateways (OMNI and The National Cancer Institute), Google and Copernic).  
Electronic searches were supplemented by checking of reference lists, handsearching 
Gynecologic Oncology and contact with authors of included studies.  No language 
restrictions were applied. 
 
Inclusion and exclusion criteria 
Population 
 Included were  
o any women with clinical suspicion of persistent or recurrent cervical cancer after 
primary treatment, on the basis of one or more of clinical history, clinical 
examination, tests (including imaging and histology).  
o any women who had had advanced stage cervical cancer (IB2-IV) treated 
previously, for example with chemoradiation with a minimum gap between 
completion of treatment and imaging of 3 months and were currently 
asymptomatic and undergoing routine follow up.  
 Excluded were:  
o studies where the population contained women within three months of completion 
of treatment for primary disease, due to problems associated with distinguishing 
treatment complications and inflammatory response from recurrence in this patient 
group 
Index test 
 Included was:  
o PET-CT using 18F-fluorodeoxyglucose as radioisotope tracer 
 Excluded was: 
o PET alone without concurrent CT 
Comparator tests 
 Included were: 
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o CT, local or whole body  
o MRI, local or whole body 
Reference standard 
 Included were:  
o histopathological findings or clinical follow up for 6 months or more or both for 
all participants (differential reference standard was accepted because of the 
difficulty of biopsy where there was no indicated lesion to biopsy in test negative 
patients) 
 Excluded were: 
o studies where only some of the participants undergoing the index test also 
received any reference standard 
Outcome 
 Included were:  
o studies that provided numerical data sufficient to create 2 x 2 tables of test results 
comparing index or comparator tests to the reference standard to provide 
information on test accuracy, giving TP,TN, FP, FN results 
o studies that provided any information on diagnostic impact: change in diagnosis 
and / or staging after PET-CT compared to existing tests or to reference standard 
o studies that provided therapeutic impact: change in treatment plan after PET-CT 
compared to existing tests or reference standard. 
Study design 
 Included were: 
o Any prospective or retrospective test accuracy studies; 
o Any diagnostic before and after studies investigating diagnostic and therapeutic 
impact with or without concurrent assessment of test accuracy 
o studies with more than 10 participants; 
 Excluded were:  
o studies on gynaecological cancers not providing separate data for the population 
with cervical cancer 
o studies that described only lesion-based analysis rather than person-based analysis 
Study selection, data extraction and Quality assessment 
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Inclusion of studies, data extraction and quality assessment were carried out in duplicate 
using predesigned and piloted data extraction forms and the QUADAS quality assessment 
tool for evaluations of test accuracy. 12 Differences were resolved by consensus and/or 
arbitration involving a third reviewer. Information on the technical quality of imaging 
technologies were also collected.   
 
Statistical analysis 
Data were extracted as two-by-two tables (true positives (TP), false positives (FP), true 
negatives (TN) and false negatives (FN). RevMan version 5.1 and STATA version 11 were 
used for analysis. Equivocal results were used in sensitivity analyses by adding the total 
number of equivocal results to each of TP, FP, FN, TN in turn to derive maximum and 
minimum variation in sensitivity and specificity.  Results were displayed graphically on 
Forest and ROC plots. 13 A bivariate model that included a random-effects term for variation 
in accuracy and threshold between studies was fitted where adequate results were available to 
derive summary estimates of sensitivity and specificity and summary ROC curves. 14 Where 
the model failed to converge or a correlation could not be estimated properly the bivariate 
model was simplified to two univariate random effects logistic regression models. 
The bivariate model has two levels corresponding to variation within and between studies in 
the meta-analysis.15 At the first level, the within study variability for both sensitivity and 
specificity is assumed to follow a binomial distribution.The sensitivity - specificity pair for 
each study must be modelled jointly within study at level one of the analysis because they are 
correlated. 
 
Methods for Subjective elicitation 
An elicitation exercise with specialists in gynaecological imaging, radiation oncology and 
gynaecological oncology was planned in anticipation of a lack of evidence with which to 
undertake an economic analysis (ref linked paper); in particular disaggregation of estimates 
of prevalence and test performance in asymptomatic and symptomatic women and direct 
comparisons of testing strategies (CT and/or MRI versus routine addition of PETCT to CT 
and/or MRI).  16 
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The subjective elicitation exercise aimed to answer 1. Value of routine PET-CT in follow-up 
of  asymptomatic women after treatment for cervical cancer  
2  Value of PET-CT imaging in detecting a recurrence in symptomatic women 
 
  Probabilities elicited  
Informed by the preliminary results of the systematic reviews of test accuracy, the research team 
decided on the data priorities for elicitation as follows:   
1) To determine the prevalence of recurrence in women with an initial diagnosis of stage IB-IVA 
cervical cancer, where patients are assumed to be disease free for a minimum of three months post-
completion of primary treatment:- in women presenting with symptoms suggestive of recurrence ,  
and in asymptomatic women.   
2) To determine the test accuracy of chest, abdominal and pelvic CT and/or MRI performed at the 
discretion of clinicians in women with an initial diagnosis of stage IB-IVA cervical cancer, who are 
assumed to be disease free for a minimum of three months post-completion of primary treatment: in 
women presenting with symptoms suggestive of recurrence ,  and in asymptomatic women ( CT/MRI 
as surveillance). 
3) To determine the test accuracy of CT and/or MRI performed at the discretion of clinicians and of 
PETCT (performed regardless of the result of initial imaging)  in women with an initial diagnosis of 
stage IB-IVA cervical cancer, who are assumed to be disease free a minimum of three months post-
completion of primary treatment: in women presenting with symptoms suggestive of recurrence ,  and 
in asymptomatic women (CT and/or MRI +PETCT used for surveillance).   
 
The initial elicitation exercise (N=9) was facilitated during an educational meeting in order to 
evaluate the accessibility of materials for respondents. Following the success of the initial 
elicitation, as judged by the face validity of findings fed back to participants, elicitations from 
subsequent specialists (N=12) were conducted using self-completed questionnaires.  
Subjective estimates of the prevalence of cervical cancer recurrence in two hypothetical 
cohorts of symptomatic and asymptomatic women and the accuracy of two testing strategies 
(CT and/or MRI performed at the discretion of clinicians and the routine addition of PET-CT 
(performed regardless of the result of CT and/or MRI) were elicited. Participants completed 
the elicitation exercise independently in order to ensure that any variation within and across 
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disciplines could be captured.  The elicitation exercise comprised an 11 page anonymous self-
administered questionnaire (Appendix S1). We collected data on experience, use of current 
imaging techniques and participant’s use of PET-CT. We asked what participants considered 
to be the minimum important clinical difference (in terms of test error rates) in accuracy 
between imaging with CT and/or MRI alone compared to routine addition of PET-CT to CT 
and/or MRI that they would require before the introduction of one or other imaging strategy 
into practice.  
 
Accuracy data were elicited in the form of the proportion of test errors (false positive and 
false negatives). We chose test errors as a metric of accuracy based on research suggesting 
that the clinical utility of a test is commonly conceptualised in this way. 15 17 Subjective 
estimates of test error rates and of the prevalence of cervical cancer recurrence were used to 
derive positive predictive vales and negative predictive values for asymptomatic and 
symptomatic women separately.  
We defined PPV as the proportion of women who test positive on either CT and/or MRI (and 
separately the routine addition of PET-CT) who are confirmed as having recurrence of on the 
basis of histology. NPV is defined as the proportion of women who test negative on either CT 
and/or MRI (and separately routine addition of PET-CT) who are confirmed as not having 
recurrence on the basis of a minimum of 6 months clinical follow up. Elicitation of 
prevalence and test accuracy information was undertaken using the allocation of point’s 
technique whereby respondents are asked to indicate the likelihood of a value range being a 
true estimate by allocating a proportion of 100 points to that value range (the sum of allocated 
points across each value range summing to 100). Value ranges differed depending on the 
question being asked to. For example the spread of value ranges for subjective estimates of 
the prevalence of recurrence in asymptomatic women was 0-49% including a single category 
for >50%. The spread of value ranges for subjective estimates of the prevalence of recurrence 
in symptomatic women was 51-100% including a single category of <50%. For elicitation of 
test accuracy (FP and FN) the spread of value ranges was between 0 and 50% to reflect the 
fact that a test error rate greater than 50% equates to a test accuracy that is worse than chance. 
In this way probability functions were obtained for each individual and aggregated 
mathematically to derive an average distribution for the sample. 17An aggregated mean value 
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was estimated using the average distribution and the mid-point of each value range. The 
variability of this aggregated mean was estimated by calculating the standard deviation across 
the value ranges.  
Results 
Results of systematic review of test accuracy 
Study selection and characteristics of included studies  
From 7,524 potentially relevant citations, we selected 252 full-text articles for assessment.  
240 articles were excluded, most commonly for different patient population or incorrect study 
design. Figure 1 shows the PRISMA diagram of selection process. Six studies evaluated 
PET-CT, 8 18-22  two 
 
evaluated MRI, 23 24 three evaluated CT 25-27  one evaluated both MRI 
and CT28 . Only one study gave results for both CT and / or MRI versus CT and/or MRI with 
whole body PET-CT with the same reference standard of histology or clinical evidence of 
disease in one table so comparisons can be drawn. 19 Unfortunately the study did not specify 
the part of the body imaged by CT/MRI. Supplementary Tables S1,S2,S3,S4,S5 describe 
characteristics of included patients. The total number of patients in the studies ranged from 
20 to 75 but some of the studies included women with any gynaecological cancers and others 
reported imaging results for both recurrent and primary cervical cancer.  
 
Of note, the MRI/CT studies were published between 1981-2000 and none used current 
standard imaging methods. The quality of the studies was poor; in particular very little 
clinical information about participants was given and incorporation bias was inevitable for 
index test negative patients as a result of the reference standard being clinical follow up 
which is likely to have included imaging. (Supplementary Table -S6) 
 
Included studies for each study question 
1. Value of routine PET-CT in follow-up of women after treatment for cervical cancer. Two 
included studies included asymptomatic women but did not present data for asymptomatic 
women separately from women with symptoms. 21 24   
2. Value of PET-CT imaging in detecting a recurrence in case of symptoms. We found six 
relevant studies , 8 18‐22 .  
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3. Value of PET-CT imaging in order to define the treatment strategy. Only one  included 
PET-CT study reported information on diagnostic and therapeutic impact.8  
Statistical results for accuracy of imaging  
The sensitivities and specificities of detection of local and distant recurrence with PET-CT 
ranged between 83%-100% and 71%-100% respectively. For distant recurrence alone the 
sensitivity of PETCT was 86% and the specificity 100%. The summary estimate of the 
sensitivity of PET-CT for detection of cervical cancer recurrence was 92.2 (95%CI 85.1, 
96.0) and specificity 88.1 (95% CI 77.9, 93.9). (Figures 2, 3) A sensitivity analysis, omitting 
one study ( Amit et al, 2006)18 that reported accuracy for distant recurrence only did not 
affect accuracy estimates to any significant degree (sensitivity 92.6 (95%CI 85.3, 96.4); 
specificity 87.3 (95%CI 76.6, 93.5). Only one study (N=12) gave results for both standard  
imaging alone and standard imaging with whole body PET-CT with the same reference 
standard of histology or clinical evidence of disease in one table. Unfortunately the part of the 
body imaged with standard imaging was not mentioned in the paper. This demonstrated 
sensitivity and specificity of CT and/or MRI of 25% and 50% respectively whilst the addition 
of PET-CT to this imaging strategy resulted in a  sensitivity and specificity of 100%.19 
 
Meta-analysis for MRI or CT test accuracy studies was not possible because of considerable  
clinical heterogeneity. The sensitivity and specificity of MRI in pelvic recurrence varied 
between 82% - 100% and 78% - 100% respectively. The sensitivity and specificity of CT in 
pelvic recurrence (excluding equivocal results) varied between 78% - 93% and 0% - 95% 
respectively. (data not shown) 
 
Results for Subjective elicitation 
 
Subjective estimation of the prevalence of recurrence was elicited from all twenty one 
respondents and subjective estimation of accuracy from 18 respondents. Responses from 
individuals who received pre-elicitation education in the form of a lecture did not appear to 
differ from those completing self-administered questionnaires only. The self-reported 
characteristics of respondents and their reported use of imaging technologies are outlined in 
Supplementary Table S7 and Figure 4. The mean elicited prevalence of recurrence in women 
presenting with symptoms a minimum of three months after completion of primary treatment 
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was 47.8% (sd 20.8) and for asymptomatic women was 16.7% (sd 13.1). Subjective estimates 
of the accuracy of the two testing strategies and the minimum important difference between 
them considered sufficient to warrant the routine addition of PET-CT for the detection of 
cervical cancer recurrence are shown in Table 1. Mean elicited estimates of the increase in 
PPV of CT and/or MRI plus PET-CT compared to CT and/or MRI alone in symptomatic 
women was 2.6 and the increase in NPV 3.6. For asymptomatic women the mean elicited 
increase in PPV was 4.6 and in NPV 3.4. 
 The minimum important elicited increase in accuracy of the addition of PET-CT to CT 
and/or MRI considered necessary to warrant introduction of PET-CT as a routine 
investigation in this sample of clinical experts was similar for asymptomatic (a mean 8.7% 
reduction in false positives and 6.3% reduction in false negatives) and symptomatic women 
(a mean 7.7% reduction in false positives and 6.4% reduction in false negatives).  Thus the 
subjective estimate of incremental accuracy resulting from the routine addition of PET-CT to 
MRI and/or CT was estimated to be smaller than the elicited minimum important difference 
in accuracy required to justify its use for the investigation of women after completion of 
primary treatment for cervical cancer.  
Comparison with systematic review results 
We found that elicited estimates of the accuracy of CT and/or MRI plus PET-CT compared to 
CT and/or MRI alone in symptomatic women were similar to estimates of accuracy in the 
literature (Table 2). The absence of published estimates of accuracy in asymptomatic women 
precluded a comparison in this group. Elicited specificities of CT and/or MRI and CT and/or 
MRI plus PET-CT were comparable to literature based estimates in mixed symptomatic and 
asymptomatic populations whilst elicited sensitivities were lower. A lower sensitivity would 
be expected in a homogenous asymptomatic population compared to a mixed symptomatic 
and asymptomatic population and therefore this finding supports the validity of elicited 
estimates. 
 
DISCUSSION 
Intercollegiate guidelines recommend the use of PET-CT in patients with recurrent cervical 
cancer considered for exenterative surgery or where prior imaging is equivocal. The evidence 
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underpinning these recommendations were largely derived from studies of diagnostic 
accuracy of PET-CT in primary cervical cancer to predict lymph node metastasis. 29-31. In 
addition, SIGN guidelines also recommend a PET-CT scan 9 months after 
chemoradiotherapy based on limited evidence 32 33 
 
 
We evaluated evidence to answer three relevant questionsvalue of PET/CT in routine follow-
up in asymptomatic women, the value of PET/CT in women with symptoms suspicious of 
recurrence and the value of PET/CT in defining therapy. In particular, we sought to identify 
the additional value of PET/CT over conventional CT/MRI imaging in these clinical 
scenarios. Our systematic review finds that evidence of diagnostic accuracy to support the use 
of whole body PET-CT in addition to standard CT or MRI imaging in all 3 scenarios is scarce 
and of poor quality . We found that published studies often do not distinguish between 
applications for surveillance versus diagnosis in suspected recurrence.   There was scanty 
information on imaging as routine follow up for asymptomatic patients. Only one paper on 
diagnostic impact was found8. In particular the MRI and CT studies did not reflect current 
practice standards and thus the true additional value of PET/CT in these scenarios is unclear. 
In fact, most included PET/CT studies present results of diagnostic accuracy of PET/CT 
alone rather than the accuracy of PET/CT in comparison to CT/MRI. Thus the additional 
value of PET-CT in these settings is unclear. Only meta-analysis of PET-CT results was 
possible and results from the literature were coherent with findings of the subjective 
elicitation exercise.   
 
The elicited estimated increase in accuracy of adding PET-CT to MRI and/or CT was less 
than the elicited minimum important difference in accuracy required to justify the routine 
addition of PET-CT for the investigation of women after completion of primary treatment for 
cervical cancer.  
 
Our systematic review was comprehensive in its scope and search. We conducted the review 
in line with contemporary recommendations. Our search of literature aimed to minimise the 
risk of selection and publication bias.  We made considerable efforts to find appropriate input 
values on effectiveness of treatment for the decision analytic model which is based on best 
available evidence. All assumptions used in the model were agreed by the team based on 
expert advice a priori. 
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Experts used in the elicitation exercise were representative in specialty and expertise of 
decision makers in recurrent cervical cancer. The subjective elicitation exercise was carried 
out using expert opinion, before any economic analysis was undertaken and produced data 
not available in the published literature.  The definition of expert for the purposes of 
subjective elicitation is not considered restricted to hands-on experience of a technology as 
subjective beliefs are shaped by factors other than first-hand experience such as interaction 
with colleagues, published estimates of accuracy and knowledge of the technology. 17  
 
Elicited estimates of accuracy of CT, MRI and PET-CT are plausible and reflect the fact that 
the accuracy of imaging tests is likely to be greater in symptomatic compared to 
asymptomatic women. In addition, the pattern of elicited estimates of accuracy in 
asymptomatic women is plausible given the lower prevalence of recurrence in asymptomatic 
women. Elicited estimates of accuracy also reflect a greater likelihood of an improvement in 
NPV compared to PPV in both symptomatic and asymptomatic women which is consistent 
with the probability of a larger number of false positives with the addition of PET-CT to 
current imaging practice. Importantly, elicited estimates of prevalence and accuracy had face 
validity as judged by feedback to clinical experts who participated in the face to face 
elicitation exercise.  
 
We did not evaluate selective use of PET-CT subsequent to initial CT/MRI imaging, which is 
recommended practice. 10 11 However, the systematic searches did not identify any papers to 
support a selective approach either. In fact only one paper reports impact of PET-CT on 
guiding therapy. 8 This work is part of a larger National Institute of Health Research/Health 
Technology Assessment (HTA reference 09/29/02) funded evaluation of the accuracy and cost 
effectiveness of PET-CT in recurrent cervical cancer.16 We identified the best inputs from 
evidence in order to construct a decision analytic model to determine the cost effectiveness of 
additional PET-CT in recurrent cervical cancer (linked submission). 
 
Current guidelines support the use of PET-CT in suspected recurrent or persistent disease 
after initial imaging and as surveillance in asymptomatic women after completion of 
chemoradiation for primary treatment. This is not supported by evidence from this systematic 
review of the literature or by the elicitation exercise. Few test accuracy studies were 
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identified as being relevant to current imaging practice. This study finds that the accuracy of 
PET-CT in recurrent cervical cancer is not yet proven. However the authors acknowledge that 
lack of evidence of value (of PET-CT) is not the same as evidence to support lack of value . 
 
Good quality, adequately powered studies directly comparing the test accuracy of the 
addition of PET-CT to MRI and/or CT imaging alone in women with recurrent and persistent 
cervical cancer are needed.  Studies also need to investigate the impact of additional PET-CT 
on change in diagnosis, work-up and change in the treatment plan.  We also recommend that 
a national register of women considered for exenterative surgery for recurrent cervical cancer 
be established to prospectively collect data on imaging, decision making and outcomes of 
treatment. To our knowledge, although conditional probabilities have been undertaken this is 
the first specific example of elicitation of test accuracy estimates and demonstrates the value 
of this approach to inform subsequent modelling where primary data is scanty or unreliable. 
17 Further test accuracy elicitation exercises will be required to confirm the validity of this 
approach and for comparison of test accuracy elicitation using other test accuracy metrics. 
Investigation of the benefit of face to face pre-elicitation education on the validity of 
responses is warranted as this has an impact on the methods of elicitation that are possible 
(for example the use of postal and internet based questionnaires), the resources required and 
response rate. 
 
Conclusions 
Our study (and the linked economic evaluation) raises two important issues – firstly the 
paucity of robust evidence on which to base decision making in the diagnosis and treatment 
of recurrent cervical cancer and secondly a broader question on how rapidly evolving, often 
‘glamorous’ technology can be robustly evaluated prior to incorporation into routine clinical 
care. The use of PET-CT in recurrent cervical cancer and its endorsement by national 
guidelines is not supported by published literature. Consideration to revise national guidelines 
and/or prospective study in a national registry of exenterative surgery for recurrent cervical 
cancer to evaluate the effectiveness of PET-CT in this setting is necessary.  
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Box 
 
What is currently known on the topic? 
 PET-CT scan is currently used to triage patients for exenterative surgery and is 
recommended for surveillance after treatment for advanced stage cervical cancer. 
These indications for use are endorsed by national guidelines.  
 However, the diagnostic accuracy of additional PET-CT in either indication is not 
known.  
 
What this study adds 
 Test accuracy studies in recurrent cervical cancer lack currency, are of poor quality 
and of limited applicability to current practice. Published literature does not support 
the use of additional PET-CT in selecting patients for exenterative surgery or its use 
for surveillance in asymptomatic patients after completion of primary treatment.  
 The elicited estimated increase in accuracy of adding PET-CT to MRI and/or CT is 
less than the elicited minimum important difference in accuracy required to justify the 
routine addition of PET-CT for the investigation of women after completion of 
primary treatment for cervical cancer.  
 There is an urgent need to revise national guidelines and/or prospectively investigate 
the test accuracy of additional PET/CT in recurrent cervical cancer.  
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Figure 1. PRISMA diagram of selection process – diagnostic systematic review 
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Fig: 2. Forest Plot: Sensitivity and Specificity PETCT studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The bivariate model failed to converge for estimation of the accuracy of PETCT and 
estimates are therefore based on a univariate random effects meta-analyses for 
sensitivity and specificity separately. The summary estimate of the sensitivity of PET-
CT for detection of cervical cancer recurrence was 94.8% (95%CI 91.2, 96.9) and 
specificity 86.9 (95% CI 82.2, 90.5).  
 
 
 Fig: 3. Forest Plot: Sensitivity and Specificity CT studies 
 
 
 
 
 
Summary estimate of sensitivity of CT from a bivariate meta-analysis: 89.64 (95% CI 81.59, 
94.41). Summary estimate of specificity of CT 76.00 (95% CI 43.68, 92.82) 
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Supplementary Table 1 Studies included in the diagnostic review 
Study name, date Index test (s)  Reference standard  Suspected recurrence/ 
asymptomatic 
Number 
evaluable 
in study 
Amit 2005 CT then whole body 
PET-CT 
Histopathology Suspected  11** 
Cetina 2011 1. Abdominal or pelvic 
CT and PET-CT 
2. Abdominal or pelvic 
CT alone 
Histopathology, serial 
imaging studies or clinical 
follow up. Length of follow 
up not specified 
Suspected  16 
Chung 2012 Whole body PET-CT Histopathology, radiology 
and/or clinical follow up. 
(range 6 – 307 months; 
median 24 months) 
Asymptomatic (56.9%) 
or suspected (43.1%) 
276 
Grisaru 2004 1. CT and/or MRI plus 
PET-CT (skull to mid-
thigh).  
2.  CT and/or MRI 
alone 
Histopathology, radiology 
and/or clinical follow up  
Suspected 12 
Kitajima 2008 Imaging then whole 
body PET-CT  
Histopathology, clinical 
follow up for >1 yr, tumour 
marker levels alone or with 
CT or PET-CT 
Suspected 52 
Lee 2011 Imaging then whole 
body PET-CT 
Histopathology, radiology 
and/or clinical follow up, or 
reaction to post-CHRT 
treatment (follow up 6 
months) 
Suspected  51 
Mittra 2009 Imaging then whole 
body PET-CT 
Histopathology or clinical 
follow up 
Suspected and 
symptomatic 
(disaggregation not 
possible) 
30 
Pallardy 2010 1. CT and / or MRI 
then head, thorax and 
abdominal PET-CT 
2. CT or MRI alone 
Histopathology or clinical 
follow up (range 23.6 – 69.8 
months; median 48 months) 
Suspected  40 
Sironi 2007 Imaging then whole 
body PET-CT 
Histopathology, clinical 
follow up with radiology for 
>6 months 
Suspected 12 
Hatano 1999 MRI (pelvic) Histopathology  Unclear 35* 
Weber 1995 MRI (pelvic)  Histopathology, clinical 
follow up for up to 4 yrs 
Suspected 37* 
Heron 1988 CT (abdomen) Histopathology, clinical 
follow up 
Suspected 70* 
Park 2000 CT (chest, abdomen 
and pelvis)  
Histopathology, tumour 
marker, CT 
Suspected 36 
Walsh 1981 CT (abdomen and 
pelvis)  
Histopathology  Probably suspected 33* 
Williams 1989 CT and / or MRI (both 
pelvic)  
Histopathology  Suspected 20* 
* gives test results for local recurrence only, not for all recurrence 
** gives test results for extra-cervical lesions only  
 
  
                                 Supplementary Table 2 Definitions of reference standards presented in 
included studies 
Study 
Reference standard 
histopathological 
 findings 
follow-up 
clinical radiological 
PET-CT 
Amit 
2005 
histopathological examination during biopsy, 
random sampling of nodes 
- - 
Cetina 
2011 
histopathological examination during biopsy Clinical course (lemgth not 
specified) 
Serial imaging 
(length not 
specified)
 
   
Chung 
2012 
histopathological examination during biopsy physical and gynaecological 
examination, tumour marker 
levels (6-307 months) 
Serial imaging 
(6-307 months) 
Grisaru 
2004 
histology during surgical exploration or guided 
biopsies 
clinical outcomes (all negative 
tissue diagnosis were followed 
to confirm negative histology) 
radiological  
Kitajim
a 2008 
histopathological examination (n=21) clinical follow-up for periods longer than 1 year on 
the basis of tumour marker levels AND contrast-
enhanced CT findings (n=14), tumour marker levels 
AND PET-CT findings (n=12), tumour marker levels 
alone (n=5) 
Lee 
2011 
histopathology Follow up lasting for 6 months 
or longer: reacted to post-CHRT 
treatment.  
Follow up lasting 
for 6 months or 
longer, increase 
in size or number 
of affected areas 
i iMittra 
2009 
histological evaluation (n=23) clinical follow-up (n=7) - 
Pallardy 
2010 
Histological evaluation Follow up range 23.6-69.8 
(median) 48 months according 
to RECIST criteria 
Follow up range 
23.6-69.8 
(median) 48 
monthsCT or 
MRI according to 
RECIST criteria 
Sironi 
2007 
histopathological findings during surgery or 
imaging-guided FNA biopsy in patients who were 
positive on PET-CT 
If –ve on PETCT - clinical outcomes with CT or MR 
imaging over at least 6 months 
MRI 
Hatano 
1999 
histopathological findings during multiple punch 
biopsies and cytology of tumour site only  
- - 
Weber 
1995 
Histopathology and/or surgical outcomes (n=34) clinical follow up for at least 4 
years (n=3) 
 
CT 
Heron 
1988 
histological evaluation: at EUA (n=4), by 
laparotomy(n=7) and by CT-guided biopsy (n=3) 
unequivocal progressive clinical 
course (n=25): inc 2 post-
mortem proof,. 17 - supportive 
evidence of deterioration on 
follow-up. For 31 patients with 
–ve test was only considered to 
- 
Study 
Reference standard 
histopathological 
 findings 
follow-up 
clinical radiological 
be free of recurrence if clinical 
condition remained stable for > 
2 years and/or histology 
Park 
2000 
percutaneous lymph node biopsy (n=10), biopsy 
of the pelvic mass (n=3) 
tumour marker study and CT at 
3- and 6-month intervals (n=23). 
 
Walsh 
1981 
histological evaluation (n=29): by laparotomy 
(n=10), parametnial biopsy (n=6), cervical and 
vaginal biopsy (n=6), penineal biopsy (n=2), 
lymph node aspiration (n=2), autopsy (n=2), and 
bone biopsy (n=1) 
- - 
MRI and CT 
William
s 1989 
histological biopsies (n=10), hysterectomy 
specimens (n=4); open biopsy at laparotomy 
(n=2); histological proof of distant metastatic 
disease (n=4). 
- - 
 
Supplementary Table 3 Population characteristics of studies evaluating PET-CT 
Characteristics Amit 2005 
Cetina 2011  Chung 2012 Grisaru 2004 Kitajima 2008 Lee 2011 Mittra 2009 Pallardy 2010 Sironi 2007 
Total N in 
study  
75 26  430 53 52 51 30 40 25 
Number with 
recurrent 
cervical cancer 
and imaging 
results 
11 16  276 12 52 51 30 40 12 
Mean age, 
year (range) 
NR 47.2 (31-66)  52 (22-81) 
(median) 
NR 58 (37; 78) 
(median) 
53 (28-76) 50 (28; 87) 45.5 (35-81) 49.6 
FIGO Initial 
stage 
NR IB2- (n=2), 
IIB (n=8), 
IIIB (n=3), 
IVA( n=1), 
IVB (n=2) 
 IA2 (n =30); IB1 
(n=118);  
IB2 (n=16) IIA 
(n=41); IIB 
(n=45);  
IIIA (n=2) IIIB 
(n=9); IVA 
(n=8) 
IVB (n=7) 
NR Ι (n=12); II 
(n=15); III (n=21); 
IV (n=4) 
0 – (n=2), I 
(n=20), II 
(n=25), III 
(n=3), IV 
(n=1) 
IB2 (n=2); IIA 
(n=4); IIB (n=10); 
IIIA (n=1); IIIB 
(n=11); IVA (n=2) 
Ι (n=7); II 
(n=16); III 
(n=13); IV 
(n=4) 
IIB (n=6); 
IIIA (n=5); 
IIIB (n=1) 
Type of        
tumour       
pathology 
NR SCC (n=15), 
ADC (n=1) 
 SCC (n=235), 
ADC (n=27), 
Other (n=14) 
NR SCC (n=42); ADC 
(n=8); ASC (n=2) 
SCC (n=46), 
other (n=5) 
SCC (n=22); ADC 
(n=5); other (n=3) 
SCC (n=39), 
ADC (n=1) 
NR 
Prior 
treatment per 
person 
NR RT (n=1), 
CHRT 
(n=13), 
SR+RT 
(n=1), SR + 
CHRT (n=1) 
 NR NR SR+CHRT 
(n=20); SR + CH 
(n=12); CHRT 
(n=12); SR (n=8) 
SR (n=5), 
SR+RT 
(n=4), SR + 
CHRT 
(n=19), 
CHRT 
(n=23) 
NR SR+CHRT 
(n=36); 
CHRT 
(n=2); RT 
(n=1); SR 
(n=1) 
SR + CH 
(n=6); SR + 
RT (n=1); SR 
+CH +RT 
(n=5) 
Inclusion  
criteria patients with 
proven 
recurrent 
cervical 
cancer. 
Patients 
with 
previous 
cervical 
cancer who 
underwent 
CT and 
PET-CT due 
to suspicion 
of  persistent 
or recurrent 
disease 
 (1) had 
symptoms 
suspecting 
recurrence; (2) 
had new lesions 
on surveillance 
imaging studies; 
(3) had elevated 
serum tumor 
markers with or 
without 
abnormal 
imaging studies; 
(4) had 
abnormal results 
on physical or 
cytologic 
examination on 
routine 
surveillance; (5) 
wanted 
surveillance 
PET-CT scan for 
fear of 
recurrence 
without 
evidence of 
disease. 
patients with 
proven 
gynaecological 
malignancy 
patients who had 
undergone 
treatment for 
histopathologically 
proven uterine 
cervical cancer; 
who had suspected 
recurrence 
Cases at risk 
for 
recurrence on 
the basis of 
clinical 
symptoms, 
signs or 
raised  
antigen levels 
or who had 
abnormal 
imaging 
results.  
patients with 
histologically 
confirmed 
carcinoma of the 
uterine cervix who 
were subjected to 
primary treatment 
with curative 
intention and who 
reached complete 
remission after 
initial treatment.  
Suspected 
recurrence 
from 
physical 
examination 
and / or 
cervical 
smear and / 
or  antigens 
and / or 
conventional 
imaging 
every 6 
months over 
a 5 year 
period, 
minimum 3 
month 
follow up 
after the 
post 
treatment 
PET-CT 
scan 
patients who 
had 
undergone 
primary 
surgical 
treatment and 
postoperative 
adjuvant 
therapy for 
uterine 
cancer. 
Exclusion 
criteria 
NR NR  (1) previous 
diagnosis of 
another 
malignant 
disease (2) 
follow up 
duration less 
than 6 months 
(3) skin or 
pulmonary 
lesions or 
impaired renal 
function likely 
to raise SCC 
antigen levels.  
NR NR Other 
malignancies. 
Refused 
PETCT for 
financial 
reasons 
other malignancies, 
had an initial 
diagnosis of 
advanced cancer 
cervix not suitable 
for treatment with 
curative intent, or 
did not achieve 
complete 
remission. 
NR negative 
(normal) 
findings at 
routine 
follow-up 
examinations, 
serum 
glucose level 
of more than 
200 mg/dl. 
     
Supplementary Table S4.  Quality of included studies in systematic review 
Study 
name, 
date 
Test  1 2 3 4 5 6 7 8 9 10 11 12 Comments 
Amit 2005 PET CT Y N Y U Y Y N U N N N Y Extra–pelvic 
recurrence 
only 
Cetina 
2011 
PET-CT 
CT 
- 
N 
N  
U 
U N 
Y 
 
U 
Y U N N  
Y 
xxx  
Chung 
2012 
PET-CT Y Y Y U N  
U 
Y  
U 
N N  
NA 
xxx  
Grisaru 
2004 
PET CT 
(CT +/- 
MRI) 
U N Y U Y Y N Y N N NA Y  
Kitajima 
2008 
PET CT  Y Y Y U Y Y N Y Y N NA Y  
Lee 2011 PET-CT Y Y N U  
Y 
U Y U Y N NA xxx  
Mittra 
2009 
PET CT Y Y Y U Y U N U Y N NA Y  
Pallardy 
2010 
PET-CT Y Y Y U Y U Y U U N NA xxx  
Sironi 
2007 
PET CT Y Y Y Y Y Y N Y Y N NA Y  
Hatano 
1999 
MRI Y U Y U Y Y N U Y N N N Tumour site 
only  
Weber 
1995 
MRI U U Y U Y Y N U N N NA N Pelvic 
recurrence 
only 
Heron 
1988 
CT Y U N U N Y N U Y N NA N Local 
recurrence 
only 
Park 2000 CT U U N U Y N N U U N NA N  
Walsh 
1981 
CT Y Y Y Y Y Y N U N Y Y N Pelvic 
recurrence 
only  
Williams 
1989 
MRI/CT Y U Y U Y Y N Y N N NA N Local 
(central) 
recurrence 
only  
Y = yes, N = no , U = unclear, NA = not applicable 
1 – representative spectrum, 2 – selection criteria clearly described, 3 – acceptable reference standard, 
4 – acceptable delay between imaging tests, 5 – partial verification avoided, 6 – reference standard 
independent of the index test, 7 – tests described in sufficient detail for replication, 8 – reference 
standard/index test blinded, 9 – relevant clinical information, 10 – uninterpretable results reported, 11 
– withdrawals explained, 12- technical quality.  
 
Supplementary Table 5. Characteristics of respondents to the elicitation exercise - Speciality/ 
Designation; years of experience; years of using PETCT 
Speciality & years of 
experience* 
Use of imaging technologies (% of symptomatic consultations for 
recurrence) 
MRI CT MRI 
and CT 
Experience with PETCT 
Gynaecological oncology 
(8 yrs) 
20 20 60 No 
Gynaecological oncology 
(15 yrs) 
70 90 60 No 
Radiology 
(10 yrs) 
NA NA NA NA 
Radiology 
(20 yrs 
NA NA NA NA 
Obstetrics and 
Gynaecology (SPR) 
(5 yrs) 
30 60 10 1 yr. 
“To decide on treatment planning: Need 
surgery?” 
Gynaecological oncology 
(5 yrs) 
10 80 10 4 yrs. 
“To decide on treatment planning: Prior to 
exenteration” 
Gynaecological oncology 
(21 yrs) 
NS NS NS No 
Not reported 
(7 yrs) 
“depends on 
symptoms...MRI 100% if 
pelvic symptoms” 
3 yrs. 
“To exclude distant recurrence in patients 
with proven local recurrence” 
Gynaecological oncology 
(10 yrs as a consultant) 
50 30 30 5 yrs. 
“Patients undergoing primary 
chemoradiation to determine extent of any 
lymphadenopathy. 
Patients with local recurrence after 
surgery prior to chemoradioation to 
determine extent of lymphadenopathy. 
Prior to consideration of exenteration” 
Gynaecological oncology 
(15 yrs) 
70 30 0 3 yrs. 
“Isolated central pelvic recurrence to 
confirm no metastatic disease prior to 
exenteration” 
Gynaecological oncology 
(3 yrs as a consultant) 
10 90 0 3 yrs. 
“To clarify nature of lesions seen on CT or 
MRI and to rule out other sites of disease if 
further surgey contemplated.” 
Gynaecological oncology 
(15 yrs) 
25 50 25 2 yrs. 
“Suspected recurrence. 
Consideration for exenterative surgery.” 
Gynaecological oncology 
(10 years) 
10 80 10 3 yrs 
“If recurrence suspected on the basis of 
clinical examination / CT / MRI.” 
Gynaecological oncology 
(28 years) 
100 0 0 “Assessment of multiple site recurrence” 
Gynaecological oncology 
(5 yrs) 
20 30 50 2 yrs 
“Pre-exenteration or if biopsy difficult / 
inconclusive” 
Gynaecological oncology 
(3 yrs as a consultant) 
60 10 30 3 yrs 
“After initial imaging to determine 
suitability for radical salvage treatment to 
help exclude occult distant mets” 
Oncology 
(NS) 
20 60 20 3 yrs 
“? local recurrence where MRI cannot 
differentiate between recurrence and 
effects of radiotherapy. 
Proven local recurrence for staging prior 
to exenteration” 
Gynaecological oncology 
(34 yrs) 
0 90 10 8 yrs 
“Those with advanced disease or recurrent 
disease. Those requiring surgery following 
radiotherapy or chemoradiation.” 
Gynaecological oncology 
(3 yrs) 
20 20 60 1 yr 
“If CT/MRI positive for central recurrence 
and considering exenteration as a 
management option” 
Gynaecological oncology 
(30 yrs) 
30 50 20 3 yrs 
“If further treatment is being considered -
especially exenteration” 
Gynaecological oncology 
(30 yrs) 
30 40 30 3 yrs 
“Exenteration candidates.Equivocal 
CT/MRI “ 
All respondents were consultants in their discipline with the exception of one specialist registrar 
(SPR). Both Consultants in Radiology had experience in PET-CT but declined to  
comment on requests for imaging based on clinical scenarios 
*Years of experience were variably reported as years practising in a discipline or years practising as a 
consultant. Where respondents clarified this it is indicated in the table. 
NS: not stated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix S1. Questionnaire for Subjective elicitation of probabilities  
 
THE USE OF PETCT IN THE INVESTIGATION OF RECURRENT CERVICAL CANCER 
Currently in the United Kingdom, patients with suspected cervical cancer recurrence will 
undergo 
 clinical examination (rectovaginal and speculum examination, assessment of 
inguinal/ supraclavicular lymph nodes) 
 cross sectional imaging  by MRI (Magnetic Resonance Imaging) or CT (Computed 
Tomography) of chest, abdomen and pelvis 
 examination under anaesthesia, histological confirmation of any vaginal vault mass 
by biopsies. 
 
The HTA project is evaluating the added value of PET/CT to current imaging practice for 
restaging women with recurrent cervical cancer. Information from the elicitation exercise will 
be used to complement the findings of a systematic review in order to achieve objective 1 in 
figure 1 below: 
Fig 1: Imaging modalities and treatment strategies in women with recurrent cervical cancer 
 
 
The accuracy of PETCT in addition to CT/MRI will be examined for women with initial stage 
I-IV disease presenting with symptoms and for surveillance of asymptomatic women with 
initial stage 1B2-IV. 
BACKGROUND INFORMATION 
 
The following information is to assist with interpretation of the information we are about to 
elicit. For example, your estimates of accuracy may vary according to your speciality or to 
your experience of using PETCT. 
 
1) Speciality 
 
 
2) Years working in your current speciality 
 
 
3) In any one single follow up consultation for patients under surveillance following an initial 
diagnosis of cervical cancer, in what % of patients do you estimate using MRI alone; CT 
alone; a combination of CT and MRI? 
 
Indicate the % of patients who you estimate receive (CT); (MRI );(CT and MRI)ensuring the 
total % of patients sums to 100% 
 
Imaging % of patients receiving tests in any one follow up consultation 
CT alone  
MRI alone  
CT + MRI  
TOTAL 100% 
 
 4) Do you currently use PETCT as part of the investigation of recurrent cervical cancer?  
 
Yes / No 
 
 
4 a) If you answered ‘Yes’ to Q.4, please state how long you have been using PETCT as 
part of the investigation of recurrent cervical cancer 
 
 
 
4 b) If you answered ‘Yes’ to Q.4, please briefly describe in which patients or circumstances 
you use PETCT 
  
WHAT IS THE PREVALENCE OF RECURRENT DISEASE? 
The first piece of information we would like to elicit from you is your estimate of the 
prevalence of recurrent cancer in symptomatic and asymptomatic women 3 months post 
completion of primary treatment.  
 
4) Of women with a mix of initial stage I-IV cervical cancer presenting with symptoms 
suspicious for recurrence a minimum of 3 months post completion of treatment, what % 
would you estimate to have recurrent disease? 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
 
% of symptomatic 
women with recurrence 
confirmed 
<50% 51-60% 61-70% 71–80% 81 –90% 90-100% 
Points out of 100 
      Total 
=100 
 
 
5) Of asymptomatic women with a mix of initial stage IB2-IV cervical cancer a minimum of 3 
months post completion of treatment, what % would you estimate to have recurrent disease? 
 
% of asymptomatic 
women with recurrence 
confirmed 
0-10% 11–20% 21-30% 31-40% 41-50% >50% 
Points out of 100 
      Total 
=100 
  
ACCURACY OF IMAGING IN 
SYMPTOMATIC 
INITIAL STAGE 1-IV CERVICAL 
CANCER  
The use of MRI and/or CT alone compared to the use of MRI and/or CT + PETCT in the 
diagnosis of recurrence in patients with an initial diagnosis of  
stage I to IV cervical cancer. 
 
 
 
-All patients are assumed to be a minimum of 3 months post completion of initial treatment 
(surgery+/- chemotherapy or chemotherapy only).  
 
-All patients are assumed to be symptomatic and have had a clinical examination which may 
be under anaesthesia (histological confirmation of any vaginal vault mass by biopsies) or not 
under general anaesthesia (rectovaginal and speculum examination, assessment of inguinal/ 
supraclavicular lymph nodes).  
 
-Patients subsequently receive either: 
-CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination. In other words clinical examination is not used to triage patients for further 
imaging with CT and/or MRI; CT and/or MRI are used as an add on to clinical examination. 
OR 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination and PETCT. In other words CT and/or MRI  are not used to triage patients for 
further imaging with PETCT ; PETCT is used as an add on to CT and/or MRI. 
-----------------------------------------------------------------------------------------------------------------
 
 
 
-Of the patients who test positive following investigation with CT and/or MRI, what 
percentage do you consider will subsequently be diagnosed as negative for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test positive with CT and/or MRI who receive a false 
positive diagnosis (are actually disease negative). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False positives (disease –ve) 
   Test positives on CT and/or MRI 0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
 
-Of the patients who test negative following investigation with CT and/or MRI, what 
percentage do you consider will subsequently be diagnosed as positive for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test negative with CT and/or MRI who receive a false 
negative diagnosis (are actually disease positive). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False negatives (disease +ve) 
   Test negatives on CT and/or 
MRI 
0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
  
SYMPTOMATIC PATIENTS 
 
ACCURACY OF CT and/or MRI 
 
The use of MRI and/or CT alone compared to the use of MRI and/or CT + PETCT in the 
diagnosis of recurrence in patients with an initial diagnosis of  
stage I-IV cervical cancer. 
 
 
 
-All patients are assumed to be a minimum of 3 months post completion of initial treatment 
(surgery+/- chemotherapy or chemotherapy only).  
 
-All patients are assumed to be symptomatic and have had a clinical examination which may 
be under anaesthesia (histological confirmation of any vaginal vault mass by biopsies) or not 
under general anaesthesia (rectovaginal and speculum examination, assessment of inguinal/ 
supraclavicular lymph nodes).  
-Patients subsequently receive either: 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination. In other words clinical examination is not used to triage patients for further 
imaging with CT and/or MRI; CT and/or MRI are used as an add on to clinical examination. 
OR 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination and PETCT. In other words CT and/or MRI  are not used to triage patients for 
further imaging with PETCT ; PETCT is used as an add on to CT and/or MRI. 
-----------------------------------------------------------------------------------------------------------------
 
 
 
 
-Of the patients who test positive following investigation with CT and/or MRI + PETCT, what 
percentage do you consider will subsequently be diagnosed as negative for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test positive with CT and/or MRI + PETCT who are 
false positives (are actually disease negative). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False positives (disease –ve) 
   Test positives on CT and/or MRI 
+PETCT 
0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
 
-Of the patients who test negative following investigation with CT and/or MRI + PETCT, 
what percentage do you consider will subsequently be diagnosed as positive for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test negative with CT and/or MRI + PETCT who are 
false negatives (are actually disease positive). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False negatives (disease +ve) 
   Test negatives on CT and/or 
MRI 
+ PETCT 
0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
 
The use of MRI and/or CT alone compared to the use of PETCT as an adjunct to  
SYMPTOMATIC PATIENTS 
 
ACCURACY OF CT and/or MRI +PETCT 
 
MRI and/or CT in the diagnosis of recurrence in patients with an initial diagnosis of  
stage I-IV cervical cancer. 
 
 
 
What do you consider the minimum important clinical reduction in the number of false 
positives (the difference in the percentage of those who test positive who are false positives 
(are actually disease negative) before introducing PETCT as an adjunct to CT and/or MRI? 
 
False positives (disease –ve) 
Test positives on  
CT and/or MRI 
+PETCT 
0 - 2% 3 - 5% 6-8% 9 - 11% 
>12% 
(please 
specify) 
 
 
 
 
What do you consider the minimum important clinical reduction in the number of false 
positives (the difference in the percentage of those who test negative who are false 
negatives (are actually disease positive) before introducing PETCT as an adjunct to CT 
and/or MRI? 
 
False negatives (disease +ve) 
Test negatives on  
CT and/or MRI 
+ PETCT 
0 - 2% 3 - 5% 6-8% 9 - 11% 
>12% 
(please 
specify) 
 
 
 
  
SYMPTOMATIC PATIENTS 
 
   
ACCURACY OF IMAGING IN 
ASYMPTOMATIC 
INITIAL STAGE 1B2-IV CERVICAL 
CANCER 
 
The use of MRI and/or CT alone compared to the use of MRI and/or CT + PETCT in the 
diagnosis of recurrence in patients with an initial diagnosis of  
stage IB2-IV cervical cancer. 
 
 
 
-All patients are assumed to be a minimum of 3 months post completion of initial treatment 
(surgery+/- chemotherapy or chemotherapy only).  
 
-All patients are assumed to be asymptomatic and have had a clinical examination which 
may be under anaesthesia (histological confirmation of any vaginal vault mass by biopsies) 
or not under general anaesthesia (rectovaginal and speculum examination, assessment of 
inguinal/ supraclavicular lymph nodes).  
-Patients subsequently receive either: 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination. In other words clinical examination is not used to triage patients for further 
imaging with CT and/or MRI; CT and/or MRI are used as an add on to clinical examination. 
OR 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination and PETCT. In other words CT and/or MRI  are not used to triage patients for 
further imaging with PETCT ; PETCT is used as an add on to CT and/or MRI. 
-----------------------------------------------------------------------------------------------------------------
 
 
 
-Of the patients who test positive following investigation with CT and/or MRI, what 
percentage do you consider will subsequently be diagnosed as negative for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test positive with CT and/or MRI who receive a false 
positive diagnosis (are actually disease negative). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False positives (disease –ve) 
   Test positives on CT and/or MRI 0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
 
-Of the patients who test negative following investigation with CT and/or MRI, what 
percentage do you consider will subsequently be diagnosed as positive for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test negative with CT and/or MRI who receive a false 
negative diagnosis (are actually disease positive). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False negatives (disease +ve) 
   Test negatives on CT and/or 
MRI 
0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
ASYMPTOMATIC PATIENTS 
 
ACCURACY OF CT and/or MRI 
 
The use of MRI and/or CT alone compared to the use of MRI and/or CT + PETCT in the 
diagnosis of recurrence in patients with an initial diagnosis of  
stage IB2-IV cervical cancer. 
 
 
 
-All patients are assumed to be a minimum of 3 months post completion of initial treatment 
(surgery+/- chemotherapy or chemotherapy only).  
 
-All patients are assumed to be asymptomatic and have had a clinical examination which 
may be under anaesthesia (histological confirmation of any vaginal vault mass by biopsies) 
or not under general anaesthesia (rectovaginal and speculum examination, assessment of 
inguinal/ supraclavicular lymph nodes).  
-Patients subsequently receive either: 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination. In other words clinical examination is not used to triage patients for further 
imaging with CT and/or MRI; CT and/or MRI are used as an add on to clinical examination. 
OR 
- CT and/or MRI at the discretion of their physician and irrespective of the results of clinical 
examination and PETCT. In other words CT and/or MRI  are not used to triage patients for 
further imaging with PETCT ; PETCT is used as an add on to CT and/or MRI. 
-----------------------------------------------------------------------------------------------------------------------
 
 
 
 
-Of the patients who test positive following investigation with CT and/or MRI + PETCT, what 
percentage do you consider will subsequently be diagnosed as negative for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test positive with CT and/or MRI + PETCT who are 
false positives (are actually disease negative). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False positives (disease –ve) 
   Test positives on CT and/or MRI 
+PETCT 
0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
 
-Of the patients who test negative following investigation with CT and/or MRI + PETCT, 
what percentage do you consider will subsequently be diagnosed as positive for recurrence 
following histology and / or clinical follow up as the gold standard tests. We are asking you to 
estimate the percentage of those who test negative with CT and/or MRI + PETCT who are 
false negatives (are actually disease positive). 
 
Indicate the likelihood of each option by allocating a total of 100 points across the 5 options. 
False negatives (disease +ve) 
   Test negatives on CT and/or 
MRI 
+ PETCT 
0 - 9% 
10 - 
19% 
20-29% 
30 - 
39% 
40 - 
49% 
Points out of 100      Total 
=100 
 
ASYMPTOMATIC PATIENTS 
 
ACCURACY OF CT and/or MRI + PETCT 
 
The use of MRI and/or CT alone compared to the use of PETCT as an adjunct to MRI 
and/or CT in the diagnosis of recurrence in patients with an initial diagnosis of stage 
IB2-IV cervical cancer. 
 
 
 
 
Before introducing PETCT as an adjunct to CT and/or MRI, what % reduction in false 
positives (the percentage of those who test positive who are actually disease free) would you 
consider necessary? 
False positives (disease –ve) 
Test positives on  
CT and/or MRI 
+PETCT 
0 - 2% 3 - 5% 6-8% 9 - 11% 
>12% 
(please 
specify) 
 
 
 
 
Before introducing PETCT as an adjunct to CT and/or MRI, what % reduction in false 
negatives (the percentage of those who test negative who actually have disease) would you 
consider necessary? 
False negatives (disease +ve) 
Test negatives on  
CT and/or MRI 
+ PETCT 
0 - 2% 3 - 5% 6-8% 9 - 11% 
>12% 
(please 
specify) 
 
 
 
 
 
 
ASYMPTOMATIC PATIENTS 
 
